Amgen Inc. (NASDAQ:AMGN) Announces $2.38 Quarterly Dividend

Amgen Inc. (NASDAQ:AMGN) declared a quarterly dividend on Friday, October 31st. Shareholders of record on Friday, November 21st will be given a dividend of 2.38 per share by the medical research company on Friday, December 12th. This represents a c) annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Friday, November 21st.

Amgen has raised its dividend payment by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 14 consecutive years. Amgen has a dividend payout ratio of 44.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Amgen to earn $21.39 per share next year, which means the company should continue to be able to cover its $9.52 annual dividend with an expected future payout ratio of 44.5%.

Amgen Price Performance

Shares of AMGN opened at $342.20 on Wednesday. The company has a market capitalization of $184.27 billion, a P/E ratio of 28.02, a P/E/G ratio of 2.61 and a beta of 0.45. The business’s 50-day moving average is $297.43 and its two-hundred day moving average is $291.24. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $345.84.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter in the prior year, the firm posted $5.58 earnings per share. The company’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Research analysts predict that Amgen will post 20.62 earnings per share for the current year.

Insider Transactions at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.76% of the company’s stock.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently modified their holdings of the business. Wealth Preservation Advisors LLC purchased a new position in Amgen during the first quarter worth $25,000. CBIZ Investment Advisory Services LLC raised its stake in Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 85 shares during the last quarter. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen during the 2nd quarter worth about $27,000. Activest Wealth Management grew its holdings in shares of Amgen by 3,433.3% during the first quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock worth $33,000 after buying an additional 103 shares in the last quarter. Finally, Evelyn Partners Investment Management LLP acquired a new position in shares of Amgen in the second quarter valued at approximately $32,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.